Trade Summary

2 days ago, Koenig Sheldon L., serving as President and CEO at Esperion Therapeutics, Inc. (ESPR), sold 53,588 shares at $3.16 per share, for a total transaction value of $169,070.14. Following this transaction, Koenig Sheldon L. now holds 2,119,111 shares of ESPR.

This sale represents a 2.47% decrease in Koenig Sheldon L.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, June 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, June 18, 2026 at 4:06 PM ET, 1 day after the trade was made.

Esperion Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.